COVID-19: Mayo Clinic is committed to taking care of our patients, learners and staff as we address the COVID-19 situation. Learn more about COVID-19 online education, resources, and live course cancellations.
Bristol-Myers Squibb Hematology - Exhibitor

 

https://www.bms.com/

Contact Information

Jacob Hallen
Jacob.Hallen@bms.com
763-913-2588
www.Revlimid.com
www.Pomalyst.com
www.Empliciti.com

Ben Hallen
Ben.Hallen@bms.com
612-306-7653
www.Revlimid.com
www.Reblozyl.com

MartyWeber
Marty.Weber@bms.com
651-271-5140
www.Inrebic.com
www.Sprycel.com
www.Idhifa.com

Virtual Exhibit Hall Home

At Bristol Myers Squibb, patients are at the center of everything we do. The goal of our cancer research is to increase quality, long-term survival and make cure a possibility. We harness our deep scientific experience, cutting-edge technologies and discovery platforms to discover, develop and deliver novel treatments for patients.

Building upon our transformative work and legacy in hematology and immuno-oncology that has changed survival expectations for many cancers, our researchers are advancing a deep and diverse pipeline across multiple modalities. In the field of immune cell therapy, this includes registrational chimeric antigen receptor (CAR) T-cell agents for numerous diseases, and a growing early-stage pipeline that expands cell and gene therapy targets and technologies. We are working to develop cancer treatments directed at key biological pathways using our protein homeostasis platform, a research capability that has been the basis of our approved therapies for multiple myeloma and several promising compounds in early to mid-stage development. Our scientists are targeting different immune system pathways to address interactions between tumors, the microenvironment and the immune system to further expand upon the progress we have made and help more patients respond to treatment. Combining these approaches is key to delivering new options for the treatment of cancer and addressing the growing issue of resistance to immunotherapy. We source innovation internally, and in collaboration with academia, government, advocacy groups and biotechnology companies, to help make the promise of transformational medicines a reality for patients.